There are 2137 resources available
827P - First real-life data on olaparib in 1st line (1stL) maintenance BRCA1/2 mutated epithelial ovarian cancer (EOC) in France: Descriptive analysis of 201 patients (pts) enrolled in the cohort temporary authorization for use (ATUc)
Presenter: Charlotte Bellier
Session: E-Poster Display
Resources:
Abstract
828P - Expected versus observed response to platinum-based chemotherapy after poly (ADP-ribose) polymerase inhibitor treatment for relapsed ovarian cancer
Presenter: Thais Baert
Session: E-Poster Display
Resources:
Abstract
829P - Regorafenib (R) or tamoxifen (T) for platinum-sensitive recurrent ovarian cancer (PSROC) with rising CA125 and no evidence of clinical or radiological disease progression: A GINECO randomized phase II trial
Presenter: Olivier Tredan
Session: E-Poster Display
Resources:
Abstract
830P - Subanalysis of a randomized phase III study comparing trabectedin and PLD vs PLD alone in patients with recurrent ovarian cancer (ROC)
Presenter: Bradley Monk
Session: E-Poster Display
Resources:
Abstract
831P - Efficacy of platinum-based chemotherapy in platinum-resistant ovarian cancer: A systematic review with pooled analysis of outcomes
Presenter: Alexey Rumyantsev
Session: E-Poster Display
Resources:
Abstract
832P - GEICO1601-ROLANDO trial: A multicentric single arm phase II clinical trial to evaluate the combination of olaparib and pegylated liposomal doxorubicin for platinum-resistant ovarian cancer
Presenter: Jose Alejandro Perez Fidalgo
Session: E-Poster Display
Resources:
Abstract
833P - Mirvetuximab soravtansine (MIRV), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin (CARBO) and bevacizumab (BEV): Final results from a study in patients (pts) with recurrent platinum sensitive ovarian cancer
Presenter: David O'Malley
Session: E-Poster Display
Resources:
Abstract
834P - A phase II study of gemcitabine, cisplatin, and bevacizumab for first recurrent and refractory ovarian clear-cell carcinoma (KCOG-G1601 trial)
Presenter: Kimihiko Ito
Session: E-Poster Display
Resources:
Abstract
835P - Clinical outcomes of advanced/ recurrent ovarian clear cell carcinoma in a multi-ethnic Asian cohort following bevacizumab and immune checkpoint inhibitor therapy
Presenter: Natalie Ngoi
Session: E-Poster Display
Resources:
Abstract
836P - Safety and efficacy of XMT-1536 in ovarian cancer: A subgroup analysis from the phase I expansion study of XMT-1536, a NaPi2b antibody-drug conjugate
Presenter: Erika Hamilton
Session: E-Poster Display
Resources:
Abstract